journal article·2026-12Open access

Synergistic Ferroptosis–Immunotherapy Nanoplatforms: Multidimensional Engineering for Tumor Microenvironment Remodeling and Therapeutic Optimization

Xiao Wei, Yanqiu Jiang, Feiyang Chenwu, Zhi Li, Jie Wan, Zhengxi Li, Lele Zhang, Jing Wang, Mingzhu Song

Nano-Micro Letters· Volume 18· Issue 1

Abstract

Abstract Emerging ferroptosis–immunotherapy strategies, integrating functionalized nanoplatforms with ferroptosis-inducing agents and immunomodulatory therapeutics, demonstrate significant potential in managing primary, recurrent, and metastatic malignancies. Mechanistically, ferroptosis induction not only directly eliminates tumor cells but also promotes immunogenic cell death (ICD), eliciting damage-associated molecular patterns (DAMPs) release to activate partial antitumor immunity. However, standalone ferroptosis therapy fails to initiate robust systemic antitumor immune responses due to inherent limitations: low tumor immunogenicity, immunosuppressive microenvironment constraints, and tumor microenvironment (TME)-associated physiological barriers (e.g., hypoxia, dense extracellular matrix). To address these challenges, synergistic approaches have been developed to enhance immune cell infiltration and reestablish immunosurveillance, encompassing (1) direct amplification of antitumor immunity, (2) disruption of immunosuppressive tumor niches, and (3) biophysical hallmark remodeling in TME. Rational nanocarrier design has emerged as a critical enabler for overcoming biological delivery barriers and optimizing therapeutic efficacy. Unlike prior studies solely addressing ferroptosis or nanotechnology in tumor therapy, this work first systematically outlines the synergistic potential of nanoparticles in combined ferroptosis–immunotherapy strategies. It advances multidimensional nanoplatform design principles for material selection, structural configuration, physicochemical modulation, multifunctional integration, and artificial intelligence-enabled design, providing a scientific basis for efficacy optimization. Moreover, it examines translational challenges of ferroptosis–immunotherapy nanoplatforms across preclinical and clinical stages, proposing actionable solutions while envisioning future onco-immunotherapy directions. Collectively, it provides systematic insights into advanced nanomaterial design principles and therapeutic optimization strategies, offering a roadmap for accelerating clinical translation in onco-immunotherapy research.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Ferroptosis and cancer prognosis · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Y. Liu, W. Zhen, Y. Wang, S. Song, H. Zhang, Na2S2O8 nanoparticles trigger antitumor immunotherapy through reactive oxygen species storm and surge of tumor osmolarity. J. Am. Chem. Soc. 142, 21751–21757 (2020). https://doi.org/10.1021/jacs.0c0948210.1021/jacs.0c09482 ↗
2. M. Yu, X. Duan, Y. Cai, F. Zhang, S. Jiang et al., Multifunctional nanoregulator reshapes immune microenvironment and enhances immune memory for tumor immunotherapy. Adv. Sci. 6, 1900037 (2019). https://doi.org/10.1002/advs.20190003710.1002/advs.201900037 ↗
3. T. Yang, S. Zhang, H. Yuan, Y. Wang, L. Cai et al., Platinum-based TREM2 inhibitor suppresses tumors by remodeling the immunosuppressive microenvironment. Angew. Chem. Int. Ed. Engl. 62, e202213337 (2023). https://doi.org/10.1002/anie.20221333710.1002/anie.202213337 ↗
4. T.T. Mai, A. Hamai, A. Hienzsch, T. Caneque, S. Muller et al., Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat. Chem. 9, 1025–1033 (2017). https://doi.org/10.1038/nchem.277810.1038/nchem.2778 ↗
5. R. Hu, C. Dai, X. Dai, C. Dong, H. Huang et al., Topology regulation of nanomedicine for autophagy-augmented ferroptosis and cancer immunotherapy. Sci. Bull. 68, 77–94 (2023). https://doi.org/10.1016/j.scib.2022.12.03010.1016/j.scib.2022.12.030 ↗
6. J.D. Mancias, X. Wang, S.P. Gygi, J.W. Harper, A.C. Kimmelman, Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 509, 105–109 (2014). https://doi.org/10.1038/nature1314810.1038/nature13148 ↗
7. E. Grignano, L. Cantero-Aguilar, Z. Tuerdi, T. Chabane, R. Vazquez et al., Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein. Cell Death Discov. 9, 97 (2023). https://doi.org/10.1038/s41420-023-01371-810.1038/s41420-023-01371-8 ↗
8. M. Conrad, D.A. Pratt, Publisher Correction: the chemical basis of ferroptosis. Nat. Chem. Biol. 16, 223–224 (2020). https://doi.org/10.1038/s41589-019-0434-z10.1038/s41589-019-0434-z ↗
9. F. Zeng, S. Nijiati, L. Tang, J. Ye, Z. Zhou et al., Ferroptosis detection: from approaches to applications. Angew. Chem. Int. Ed. Engl. 62, e202300379 (2023). https://doi.org/10.1002/anie.20230037910.1002/anie.202300379 ↗
10. H.F. Yan, T. Zou, Q.Z. Tuo, S. Xu, H. Li et al., Ferroptosis: mechanisms and links with diseases. Signal Transd. Target. Ther. 6, 49 (2021). https://doi.org/10.1038/s41392-020-00428-910.1038/s41392-020-00428-9 ↗
11. X. Chen, R. Kang, G. Kroemer, D. Tang, Broadening horizons: the role of ferroptosis in cancer. Nat. Rev. Clin. Oncol. 18, 280–296 (2021). https://doi.org/10.1038/s41571-020-00462-010.1038/s41571-020-00462-0 ↗
12. N.A. Porter, S.E. Caldwell, K.A. Mills, Mechanisms of free radical oxidation of unsaturated lipids. Lipids 30, 277–290 (1995). https://doi.org/10.1007/BF0253603410.1007/BF02536034 ↗
13. W.S. Yang, R. SriRamaratnam, M.E. Welsch, K. Shimada, R. Skouta et al., Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014). https://doi.org/10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
14. G. Lei, L. Zhuang, B. Gan, Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer 22, 381–396 (2022). https://doi.org/10.1038/s41568-022-00459-010.1038/s41568-022-00459-0 ↗
15. C. Liang, X. Zhang, M. Yang, X. Dong, Recent progress in ferroptosis inducers for cancer therapy. Adv. Mater. 31, e1904197 (2019). https://doi.org/10.1002/adma.20190419710.1002/adma.201904197 ↗
16. W. Xu, G. Guan, R. Yue, Z. Dong, L. Lei et al., Chemical design of magnetic nanomaterials for imaging and ferroptosis-based cancer therapy. Chem. Rev. 125, 1897–1961 (2025). https://doi.org/10.1021/acs.chemrev.4c0054610.1021/acs.chemrev.4c00546 ↗
17. J.P. Friedmann Angeli, D.V. Krysko, M. Conrad, Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer 19, 405–414 (2019). https://doi.org/10.1038/s41568-019-0149-110.1038/s41568-019-0149-1 ↗
18. P. Liao, W. Wang, W. Wang, I. Kryczek, X. Li et al., CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell 40, 365-378 e366 (2022). https://doi.org/10.1016/j.ccell.2022.02.00310.1016/j.ccell.2022.02.003 ↗
19. A.A. Kapralov, Q. Yang, H.H. Dar, Y.Y. Tyurina, T.S. Anthonymuthu et al., Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat. Chem. Biol. 16, 278–290 (2020). https://doi.org/10.1038/s41589-019-0462-810.1038/s41589-019-0462-8 ↗
20. S. Zanganeh, G. Hutter, R. Spitler, O. Lenkov, M. Mahmoudi et al., Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 11, 986–994 (2016). https://doi.org/10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
21. R. Eugster, M. Orsi, G. Buttitta, N. Serafini, M. Tiboni et al., Leveraging machine learning to streamline the development of liposomal drug delivery systems. J. Control. Release 376, 1025–1038 (2024). https://doi.org/10.1016/j.jconrel.2024.10.06510.1016/j.jconrel.2024.10.065 ↗
22. A. Xu, G. Wang, Y. Li, H. Dong, S. Yang et al., Carbon-based quantum dots with solid-state photoluminescent: mechanism, implementation, and application. Small 16, e2004621 (2020). https://doi.org/10.1002/smll.20200462110.1002/smll.202004621 ↗
23. P. Singh, S. Pandit, S.R. Balusamy, M. Madhusudanan, H. Singh et al., Advanced nanomaterials for cancer therapy: gold, silver, and iron oxide nanoparticles in oncological applications. Adv. Healthc. Mater. 14, e2403059 (2025). https://doi.org/10.1002/adhm.20240305910.1002/adhm.202403059 ↗
24. Y. Song, X. Xu, Z. Wang, Y. Zhao, Metal-organic framework-based nanomedicines for ferroptotic cancer therapy. Adv. Healthc. Mater. 13, e2303533 (2024). https://doi.org/10.1002/adhm.20230353310.1002/adhm.202303533 ↗
25. P. Horcajada, T. Chalati, C. Serre, B. Gillet, C. Sebrie et al., Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat. Mater. 9, 172–178 (2010). https://doi.org/10.1038/nmat260810.1038/nmat2608 ↗
26. P. Gravan, J. Pena-Martin, J.L. de Andres, M. Pedrosa, M. Villegas-Montoya et al., Exploring the impact of nanoparticle stealth coatings in cancer models: from pegylation to cell membrane-coating nanotechnology. ACS Appl. Mater. Interfaces 16, 2058–2074 (2024). https://doi.org/10.1021/acsami.3c1394810.1021/acsami.3c13948 ↗
27. R.H. Fang, A.V. Kroll, W. Gao, L. Zhang, Cell membrane coating nanotechnology. Adv. Mater. 30, e1706759 (2018). https://doi.org/10.1002/adma.20170675910.1002/adma.201706759 ↗
28. F. Danhier, O. Feron, V. Preat, To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 148, 135–146 (2010). https://doi.org/10.1016/j.jconrel.2010.08.02710.1016/j.jconrel.2010.08.027 ↗
29. D.E. Lee, H. Koo, I.C. Sun, J.H. Ryu, K. Kim et al., Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem. Soc. Rev. 41, 2656–2672 (2012). https://doi.org/10.1039/c2cs15261d10.1039/c2cs15261d ↗
30. M.J. Ko, S. Min, H. Hong, W. Yoo, J. Joo et al., Magnetic nanoparticles for ferroptosis cancer therapy with diagnostic imaging. Bioact. Mater. 32, 66–97 (2024). https://doi.org/10.1016/j.bioactmat.2023.09.01510.1016/j.bioactmat.2023.09.015 ↗
31. W. Wang, M. Green, J.E. Choi, M. Gijon, P.D. Kennedy et al., CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270–274 (2019). https://doi.org/10.1038/s41586-019-1170-y10.1038/s41586-019-1170-y ↗
32. K. Li, Z. Zhang, Y. Mei, M. Li, Q. Yang et al., Targeting the innate immune system with nanoparticles for cancer immunotherapy. J. Mater. Chem. B 10, 1709–1733 (2022). https://doi.org/10.1039/d1tb02818a10.1039/d1tb02818a ↗
33. K. Li, K. Xu, Y. He, Y. Yang, M. Tan et al., Oxygen self-generating nanoreactor mediated ferroptosis activation and immunotherapy in triple-negative breast cancer. ACS Nano 17, 4667–4687 (2023). https://doi.org/10.1021/acsnano.2c1089310.1021/acsnano.2c10893 ↗
34. D.E. Large, R.G. Abdelmessih, E.A. Fink, D.T. Auguste, Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv. Drug Deliv. Rev. 176, 113851 (2021). https://doi.org/10.1016/j.addr.2021.11385110.1016/j.addr.2021.113851 ↗
35. M.Z. Wang, T.W. Gu, Y. Xu, L. Yang, Z.H. Jiang et al., Mechanical stretching of cells and lipid nanoparticles for nucleic acid delivery. J. Control. Release 339, 208–219 (2021). https://doi.org/10.1016/j.jconrel.2021.09.02110.1016/j.jconrel.2021.09.021 ↗
36. S.G. Antimisiaris, A. Marazioti, M. Kannavou, E. Natsaridis, F. Gkartziou et al., Overcoming barriers by local drug delivery with liposomes. Adv. Drug Deliv. Rev. 174, 53–86 (2021). https://doi.org/10.1016/j.addr.2021.01.01910.1016/j.addr.2021.01.019 ↗
37. W. Wang, Y. Gao, J. Xu, T. Zou, B. Yang et al., A NRF2 regulated and the immunosuppressive microenvironment reversed nanoplatform for cholangiocarcinoma photodynamic-gas therapy. Adv. Sci. 11, e2307143 (2024). https://doi.org/10.1002/advs.20230714310.1002/advs.202307143 ↗
38. Z. Gao, J. Zhang, Y. Hou, J. Lu, J. Liang et al., Boosting the synergism between cancer ferroptosis and immunotherapy via targeted stimuli-responsive liposomes. Biomaterials 305, 122442 (2024). https://doi.org/10.1016/j.biomaterials.2023.12244210.1016/j.biomaterials.2023.122442 ↗
39. X. Kong, Z. He, Y. Zhang, Y. Fang, D. Liu et al., Intelligent self-amplifying ferroptosis-inducible nanoplatform for enhanced tumor microenvironment reconstruction and combination therapy. Chem. Eng. J. 468, 143729 (2023). https://doi.org/10.1016/j.cej.2023.14372910.1016/j.cej.2023.143729 ↗
40. M. Ghezzi, S. Pescina, C. Padula, P. Santi, E. Del Favero et al., Polymeric micelles in drug delivery: an insight of the techniques for their characterization and assessment in biorelevant conditions. J. Control. Release 332, 312–336 (2021). https://doi.org/10.1016/j.jconrel.2021.02.03110.1016/j.jconrel.2021.02.031 ↗
41. D. Hwang, J.D. Ramsey, A.V. Kabanov, Polymeric micelles for the delivery of poorly soluble drugs: from nanoformulation to clinical approval. Adv. Drug Deliv. Rev. 156, 80–118 (2020). https://doi.org/10.1016/j.addr.2020.09.00910.1016/j.addr.2020.09.009 ↗
42. R. Song, T. Li, J. Ye, F. Sun, B. Hou et al., Acidity-activatable dynamic nanoparticles boosting ferroptotic cell death for immunotherapy of cancer. Adv. Mater. 33, e2101155 (2021). https://doi.org/10.1002/adma.20210115510.1002/adma.202101155 ↗
43. S. He, J. Yu, M. Xu, C. Zhang, C. Xu et al., A semiconducting iron-chelating nano-immunomodulator for specific and sensitized sono-metallo-immunotherapy of cancer. Angew. Chem. Int. Ed. Engl. 62, e202310178 (2023). https://doi.org/10.1002/anie.20231017810.1002/anie.202310178 ↗
44. C. Jiang, X. Li, F. Pan, L. Zhang, H. Yu et al., Ferroptosis and pyroptosis co-activated nanomodulator for “cold” tumor immunotherapy and lung metastasis inhibition. Adv. Funct. Mater. 33, 2211698 (2023). https://doi.org/10.1002/adfm.20221169810.1002/adfm.202211698 ↗
45. M.A. Beach, U. Nayanathara, Y. Gao, C. Zhang, Y. Xiong et al., Polymeric nanoparticles for drug delivery. Chem. Rev. 124, 5505–5616 (2024). https://doi.org/10.1021/acs.chemrev.3c0070510.1021/acs.chemrev.3c00705 ↗
46. Z. Hong, X. Zan, T. Yu, Y. Hu, H. Gou et al., Local delivery of superagonist gene based on polymer nanoparticles for cancer immunotherapy. Chin. Chem. Lett. 34, 107603 (2023). https://doi.org/10.1016/j.cclet.2022.06.02610.1016/j.cclet.2022.06.026 ↗
47. S.D. Jeong, B.K. Jung, D. Lee, J. Ha, H.G. Chang et al., Enhanced immunogenic cell death by apoptosis/ferroptosis hybrid pathway potentiates PD-L1 blockade cancer immunotherapy. ACS Biomater. Sci. Eng. 8, 5188–5198 (2022). https://doi.org/10.1021/acsbiomaterials.2c0095010.1021/acsbiomaterials.2c00950 ↗
48. B. Yu, B. Choi, W. Li, D.H. Kim, Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy. Nat. Commun. 11, 3637 (2020). https://doi.org/10.1038/s41467-020-17380-510.1038/s41467-020-17380-5 ↗
49. Q. Zhang, X. Wang, Y. Zhao, Z. Cheng, D. Fang et al., Nanointegrative in situ reprogramming of tumor-intrinsic lipid droplet biogenesis for low-dose radiation-activated ferroptosis immunotherapy. ACS Nano 17, 25419–25438 (2023). https://doi.org/10.1021/acsnano.3c0890710.1021/acsnano.3c08907 ↗
50. P. Sun, L. Huang, Z. Li, Y. Yang, S. Lu et al., Charge-reversal biodegradable nanoplatform with ferroptosis and ICD induction for tumor synergistic treatment. Chem. Eng. J. 483, 149234 (2024). https://doi.org/10.1016/j.cej.2024.14923410.1016/j.cej.2024.149234 ↗
51. R. Fan, C. Chen, M. Mu, D. Chuan, H. Liu et al., Engineering MMP-2 activated nanoparticles carrying B7–H3 bispecific antibodies for ferroptosis-enhanced glioblastoma immunotherapy. ACS Nano 17, 9126–9139 (2023). https://doi.org/10.1021/acsnano.2c1221710.1021/acsnano.2c12217 ↗
52. L. Zhang, A. Song, Q.C. Yang, S.J. Li, S. Wang et al., Integration of AIEgens into covalent organic frameworks for pyroptosis and ferroptosis primed cancer immunotherapy. Nat. Commun. 14, 5355 (2023). https://doi.org/10.1038/s41467-023-41121-z10.1038/s41467-023-41121-z ↗
53. W. Mu, Q. Chu, Y. Liu, N. Zhang, A review on nano-based drug delivery system for cancer chemoimmunotherapy. Nanomicro Lett. 12, 142 (2020). https://doi.org/10.1007/s40820-020-00482-610.1007/s40820-020-00482-6 ↗
54. M. Sharifi, F. Attar, A.A. Saboury, K. Akhtari, N. Hooshmand et al., Plasmonic gold nanoparticles: optical manipulation, imaging, drug delivery and therapy. J. Control. Release 311–312, 170–189 (2019). https://doi.org/10.1016/j.jconrel.2019.08.03210.1016/j.jconrel.2019.08.032 ↗
55. Y. Du, M. Han, K. Cao, Q. Li, J. Pang et al., Gold nanorods exhibit intrinsic therapeutic activity via controlling N6-methyladenosine-based epitranscriptomics in acute myeloid leukemia. ACS Nano 15, 17689–17704 (2021). https://doi.org/10.1021/acsnano.1c0554710.1021/acsnano.1c05547 ↗
56. X. Zhang, H. Ge, Y. Ma, L. Song, Y. Ma et al., Engineered anti-cancer nanomedicine for synergistic ferroptosis-immunotherapy. Chem. Eng. J. 455, 140688 (2023). https://doi.org/10.1016/j.cej.2022.14068810.1016/j.cej.2022.140688 ↗
57. J. Liu, J. Zhan, Y. Zhang, L. Huang, J. Yang et al., Ultrathin clay nanoparticles-mediated mutual reinforcement of ferroptosis and cancer immunotherapy. Adv. Mater. 36, e2309562 (2024). https://doi.org/10.1002/adma.20230956210.1002/adma.202309562 ↗
58. Y.C. Chin, L.X. Yang, F.T. Hsu, C.W. Hsu, T.W. Chang et al., Iron oxide@chlorophyll clustered nanoparticles eliminate bladder cancer by photodynamic immunotherapy-initiated ferroptosis and immunostimulation. J. Nanobiotechnol. 20, 373 (2022). https://doi.org/10.1186/s12951-022-01575-710.1186/s12951-022-01575-7 ↗
59. Y. Ruan, H. Zhuang, X. Zeng, L. Lin, X. Wang et al., Engineered microbial nanohybrids for tumor-mediated NIR II photothermal enhanced ferroptosis/cuproptosis and immunotherapy. Adv. Healthc. Mater. 13, e2302537 (2024). https://doi.org/10.1002/adhm.20230253710.1002/adhm.202302537 ↗
60. L. Shi, Y. Yu, J. Li, B. Ma, X. Zhang et al., NIR-responsive Cu2–xSe@Fc nanoparticles for photothermal- ferroptosis combination therapy in esophageal cancer. J. Nanobiotechnol. 23, 356 (2025). https://doi.org/10.1186/s12951-025-03434-710.1186/s12951-025-03434-7 ↗
61. C. Huang, X. Lin, T. Lin, W. Lin, Z. Gong et al., Multifunctional nanocomposites induce mitochondrial dysfunction and glucose deprivation to boost immunogenic ferroptosis for cancer therapy. Chem. Eng. J. 466, 143012 (2023). https://doi.org/10.1016/j.cej.2023.14301210.1016/j.cej.2023.143012 ↗
62. H. Lei, Q. Li, G. Li, T. Wang, X. Lv et al., Manganese molybdate nanodots with dual amplification of STING activation for “cycle” treatment of metalloimmunotherapy. Bioact. Mater. 31, 53–62 (2024). https://doi.org/10.1016/j.bioactmat.2023.07.02610.1016/j.bioactmat.2023.07.026 ↗
63. H. Lei, Q. Li, Z. Pei, L. Liu, N. Yang et al., Nonferrous ferroptosis inducer manganese molybdate nanoparticles to enhance tumor immunotherapy. Small 19, e2303438 (2023). https://doi.org/10.1002/smll.20230343810.1002/smll.202303438 ↗
64. S. Fu, Y. Li, L. Shen, Y. Chen, J. Lu et al., Cu2WS4-PEG nanozyme as multifunctional sensitizers for enhancing immuno-radiotherapy by inducing ferroptosis. Small 20, e2309537 (2024). https://doi.org/10.1002/smll.20230953710.1002/smll.202309537 ↗
65. Y. Bao, G. Li, S. Li, H. Zhang, X. Wu et al., Multifunctional tumor-targeting carbon dots for tumor microenvironment activated ferroptosis and immunotherapy in cancer treatment. ACS Appl. Mater. Interfaces (2023). https://doi.org/10.1021/acsami.3c1386710.1021/acsami.3c13867 ↗
66. L. Yao, M.M. Zhao, Q.W. Luo, Y.C. Zhang, T.T. Liu et al., Carbon quantum dots-based nanozyme from coffee induces cancer cell ferroptosis to activate antitumor immunity. ACS Nano 16, 9228–9239 (2022). https://doi.org/10.1021/acsnano.2c0161910.1021/acsnano.2c01619 ↗
67. Y. Feng, N. Panwar, D.J.H. Tng, S.C. Tjin, K. Wang et al., The application of mesoporous silica nanoparticle family in cancer theranostics. Coord. Chem. Rev. 319, 86–109 (2016). https://doi.org/10.1016/j.ccr.2016.04.01910.1016/j.ccr.2016.04.019 ↗
68. H. Chen, J. Song, Y. Wang, T. Wang, F. Zhang et al., “Triple-Hop” nano-bomb combining CDT, PDT and immunetherapy for NIR-triggered cancer therapy. Chem. Eng. J. 481, 148268 (2024). https://doi.org/10.1016/j.cej.2023.14826810.1016/j.cej.2023.148268 ↗
69. X. Deng, T. Liu, Y. Zhu, J. Chen, Z. Song et al., Ca & Mn dual-ion hybrid nanostimulator boosting anti-tumor immunity via ferroptosis and innate immunity awakening. Bioact. Mater. 33, 483–496 (2024). https://doi.org/10.1016/j.bioactmat.2023.11.01710.1016/j.bioactmat.2023.11.017 ↗
70. W. Liang, P. Wied, F. Carraro, C.J. Sumby, B. Nidetzky et al., Metal-organic framework-based enzyme biocomposites. Chem. Rev. 121, 1077–1129 (2021). https://doi.org/10.1021/acs.chemrev.0c0102910.1021/acs.chemrev.0c01029 ↗
71. R. Liu, J. Yang, Y. Du, X. Yu, Y. Liao et al., A “one arrow three eagle” strategy to improve CM-272 primed bladder cancer immunotherapy. Adv. Mater. 36, e2310522 (2024). https://doi.org/10.1002/adma.20231052210.1002/adma.202310522 ↗
72. Y. Xu, Y. Guo, C. Zhang, M. Zhan, L. Jia et al., Fibronectin-coated metal-phenolic networks for cooperative tumor chemo-/chemodynamic/immune therapy via enhanced ferroptosis-mediated immunogenic cell death. ACS Nano 16, 984–996 (2022). https://doi.org/10.1021/acsnano.1c0858510.1021/acsnano.1c08585 ↗
73. Y. Li, Y. Duan, Y. Li, Y. Gu, L. Zhou et al., Cascade loop of ferroptosis induction and immunotherapy based on metal-phenolic networks for combined therapy of colorectal cancer. Exploration 5, 20230117 (2025). https://doi.org/10.1002/EXP.2023011710.1002/EXP.20230117 ↗
74. X. Zhao, X. Wang, W. Zhang, T. Tian, J. Zhang et al., A ferroptosis-inducing arsenene-iridium nanoplatform for synergistic immunotherapy in pancreatic cancer. Angew. Chem. Int. Ed. Engl. 63, e202400829 (2024). https://doi.org/10.1002/anie.20240082910.1002/anie.202400829 ↗
75. Y. Liu, R. Niu, R. Deng, S. Song, Y. Wang et al., Multi-enzyme co-expressed dual-atom nanozymes induce cascade immunogenic ferroptosis via activating interferon-gamma and targeting arachidonic acid metabolism. J. Am. Chem. Soc. 145, 8965–8978 (2023). https://doi.org/10.1021/jacs.2c1368910.1021/jacs.2c13689 ↗
76. D. Mendanha, J. Vieira de Castro, H. Ferreira, N.M. Neves, Biomimetic and cell-based nanocarriers: new strategies for brain tumor targeting. J. Control. Release 337, 482–493 (2021). https://doi.org/10.1016/j.jconrel.2021.07.04710.1016/j.jconrel.2021.07.047 ↗
77. R.H. Fang, W. Gao, L. Zhang, Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat. Rev. Clin. Oncol. 20, 33–48 (2023). https://doi.org/10.1038/s41571-022-00699-x10.1038/s41571-022-00699-x ↗
78. P.L. Rodriguez, T. Harada, D.A. Christian, D.A. Pantano, R.K. Tsai et al., Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971–975 (2013). https://doi.org/10.1126/science.122956810.1126/science.1229568 ↗
79. Y. Wang, H. Xu, D. Wang, Y. Lu, Y. Zhang et al., Synergistic reinforcement of immunogenic cell death and transformation of tumor-associated macrophages via an M1-type macrophage membrane-camouflaged ferrous-supply-regeneration nanoplatform. Acta Biomater. 174, 358–371 (2024). https://doi.org/10.1016/j.actbio.2023.11.04110.1016/j.actbio.2023.11.041 ↗
80. M. Chen, Y. Shen, Y. Pu, B. Zhou, J. Bing et al., Biomimetic inducer enabled dual ferroptosis of tumor and M2-type macrophages for enhanced tumor immunotherapy. Biomaterials 303, 122386 (2023). https://doi.org/10.1016/j.biomaterials.2023.12238610.1016/j.biomaterials.2023.122386 ↗
81. Y. Ma, X. Zhao, P. Tian, K. Xu, J. Luo et al., Laser-ignited lipid peroxidation nanoamplifiers for strengthening tumor photodynamic therapy through aggravating ferroptotic propagation and sustainable high immunogenicity. Small 20, e2306402 (2024). https://doi.org/10.1002/smll.20230640210.1002/smll.202306402 ↗
82. Q. Jiang, K. Wang, X. Zhang, B. Ouyang, H. Liu et al., Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy. Small 16, e2001704 (2020). https://doi.org/10.1002/smll.20200170410.1002/smll.202001704 ↗
83. T. Xu, Y. Ma, Q. Yuan, H. Hu, X. Hu et al., Enhanced ferroptosis by oxygen-boosted phototherapy based on a 2-in-1 nanoplatform of ferrous hemoglobin for tumor synergistic therapy. ACS Nano 14, 3414–3425 (2020). https://doi.org/10.1021/acsnano.9b0942610.1021/acsnano.9b09426 ↗
84. X. Yu, X. Li, Q. Chen, S. Wang, R. Xu et al., High intensity focused ultrasound-driven nanomotor for effective ferroptosis-immunotherapy of TNBC. Adv. Sci. 11, e2305546 (2024). https://doi.org/10.1002/advs.20230554610.1002/advs.202305546 ↗
85. Y. Yu, X. Shen, X. Xiao, L. Li, Y. Huang, Butyrate modification promotes intestinal absorption and hepatic cancer cells targeting of ferroptosis inducer loaded nanoparticle for enhanced hepatocellular carcinoma therapy. Small 19, e2301149 (2023). https://doi.org/10.1002/smll.20230114910.1002/smll.202301149 ↗
86. G. Song, M. Li, S. Fan, M. Qin, B. Shao et al., Boosting synergism of chemo- and immuno-therapies via switching paclitaxel-induced apoptosis to mevalonate metabolism-triggered ferroptosis by bisphosphonate coordination lipid nanogranules. Acta. Pharm. Sin. B 14, 836–853 (2024). https://doi.org/10.1016/j.apsb.2023.08.02910.1016/j.apsb.2023.08.029 ↗
87. W. Guo, Z. Wu, J. Chen, S. Guo, W. You et al., Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis. J. Immunother. Cancer (2022). https://doi.org/10.1136/jitc-2021-00438110.1136/jitc-2021-004381 ↗
88. Y. Zou, B. Jin, H. Li, X. Wu, Y. Liu et al., Cold nanozyme for precise enzymatic antitumor immunity. ACS Nano 16, 21491–21504 (2022). https://doi.org/10.1021/acsnano.2c1005710.1021/acsnano.2c10057 ↗
89. D. Li, J. Ren, J. Li, Y. Zhang, Y. Lou et al., Ferroptosis-apoptosis combined anti-melanoma immunotherapy with a NIR-responsive upconverting mSiO2 photodynamic platform. Chem. Eng. J. 419, 129557 (2021). https://doi.org/10.1016/j.cej.2021.12955710.1016/j.cej.2021.129557 ↗
90. K. Zhang, Z. Ma, S. Li, Y. Wu, J. Zhang et al., Disruption of dual homeostasis by a metal-organic framework nanoreactor for ferroptosis-based immunotherapy of tumor. Biomaterials 284, 121502 (2022). https://doi.org/10.1016/j.biomaterials.2022.12150210.1016/j.biomaterials.2022.121502 ↗
91. P. Liu, X. Shi, Y. Peng, J. Hu, J. Ding et al., Anti-PD-L1 dnazyme loaded photothermal Mn2+/Fe3+ hybrid metal-phenolic networks for cyclically amplified tumor ferroptosis-immunotherapy. Adv. Healthc. Mater. 11, e2102315 (2022). https://doi.org/10.1002/adhm.20210231510.1002/adhm.202102315 ↗
92. Y. Cai, Y. Jiang, Y. Chen, E. Cheng, Y. Gu et al., Amplifying STING activation and immunogenic cell death by metal-polyphenol coordinated nanomedicines for enhanced cancer immunotherapy. Chin. Chem. Lett. 36, 110437 (2025). https://doi.org/10.1016/j.cclet.2024.11043710.1016/j.cclet.2024.110437 ↗
93. K. Sun, J. Yu, J. Hu, W. Yang, X. Chu et al., Photothermal enhanced polyphenol-based nanofibers ameliorate catalytic efficiency of ferroptosis for synergistic tumor therapy. Chem. Eng. J. 470, 144360 (2023). https://doi.org/10.1016/j.cej.2023.14436010.1016/j.cej.2023.144360 ↗
94. T. Nie, H. Liu, Z. Fang, Y. Zheng, R. Zhang et al., Tumor microenvironment mediated spermidine-metal-immunopeptide nanocomplex for boosting ferroptotic immunotherapy of lymphoma. ACS Nano 17, 10925–10937 (2023). https://doi.org/10.1021/acsnano.3c0280310.1021/acsnano.3c02803 ↗
95. C.-M. Lai, J. Xu, B.-C. Zhang, S.-H. He, J.-W. Shao, A natural product-derived nanozyme regulator induced chemo-ferroptosis dual therapy in remodeling of the tumor immune microenvironment of hepatocellular carcinoma. Chem. Eng. J. 482, 148976 (2024). https://doi.org/10.1016/j.cej.2024.14897610.1016/j.cej.2024.148976 ↗
96. W. Guo, Z. Chen, Z. Li, H. Huang, Y. Ren et al., Cancer cell membrane biomimetic mesoporous silica nanotheranostics for enhanced ferroptosis-mediated immuogenic cell death on gastric cancer. Chem. Eng. J. 455, 140868 (2023). https://doi.org/10.1016/j.cej.2022.14086810.1016/j.cej.2022.140868 ↗
97. H. Yang, X. Yao, Y. Liu, X. Shen, M. Li et al., Ferroptosis nanomedicine: clinical challenges and opportunities for modulating tumor metabolic and immunological landscape. ACS Nano 17, 15328–15353 (2023). https://doi.org/10.1021/acsnano.3c0463210.1021/acsnano.3c04632 ↗
98. H. Wang, C. Qiao, Q. Guan, M. Wei, Z. Li, Nanoparticle-mediated synergistic anticancer effect of ferroptosis and photodynamic therapy: novel insights and perspectives. Asian J. Pharm. Sci. 18, 100829 (2023). https://doi.org/10.1016/j.ajps.2023.10082910.1016/j.ajps.2023.100829 ↗
99. H. Lee, A.K. Lytton-Jean, Y. Chen, K.T. Love, A.I. Park et al., Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 7, 389–393 (2012). https://doi.org/10.1038/nnano.2012.7310.1038/nnano.2012.73 ↗
100. P. Decuzzi, B. Godin, T. Tanaka, S.Y. Lee, C. Chiappini et al., Size and shape effects in the biodistribution of intravascularly injected particles. J. Control. Release 141, 320–327 (2010). https://doi.org/10.1016/j.jconrel.2009.10.01410.1016/j.jconrel.2009.10.014 ↗